HTG Closes Series E Preferred Stock Offering | GenomeWeb

NEW YORK (GenomeWeb News) – RNA-based testing firm HTG Molecular Diagnostics today said it has initially closed its Series E preferred stock offering.

Through a spokesperson, HTG and its investors declined to disclose the amount of the Series E round. Existing investors Novo Ventures, SROne, Merck Capital Ventures, and Fletcher Spaght participated in the round.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.